NanoViricides is trading 15.01% up now at $1.37 after announcing that its Phase II NV-387 oral-gummy Ebola trial is scheduled to begin next week.
- The trial will take place at an Ebola Treatment Center in Ituri province, Democratic Republic of Congo.
- The upcoming trial creates a near-term clinical catalyst.
- Broader biotech strength and improving risk appetite are providing additional support.